Patents Examined by Titilayo Moloye
  • Patent number: 11512273
    Abstract: Disclosed is an apparatus for the production of tissue from cells. The apparatus comprises an elongate body having at least one circumferential groove and being operable to extend, by close-fitting relationship, centrally through at least one trough. The troughs are extending in a closed path, such that the at least one of the circumferential grooves open into an inner edge of a trough. Also disclosed is a process for production of tissue from cells, via a transitioning intermediate which transitions from the cells into the tissue.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: November 29, 2022
    Assignee: MOSA MEAT B.V.
    Inventors: Jonathan Jan Breemhaar, Mark Post
  • Patent number: 11497791
    Abstract: Described herein are compositions and methods of using placental stem cell recruiting factors, more specifically, isolated placental stem cell recruiting factors. In one embodiment, isolated placental stem cell recruiting factors are delivered to a site such as a diseased or injured organ and/or body part in an amount sufficient to recruit stem cells to the site.
    Type: Grant
    Filed: February 18, 2019
    Date of Patent: November 15, 2022
    Assignee: MiMedx Group, Inc.
    Inventors: Thomas J. Koob, Rebeccah J. C. Brown
  • Patent number: 11492583
    Abstract: The disclosure relates to methods, systems and compositions for physically manipulating a muscle tissue culture either mechanically, or manually, or both. Specifically, the disclosure relates to systems and methods of physically manipulating, either mechanically or manually, a resilient container of bioprinted tissue culture having non-random three dimensional cell structure by elongation, compression, torque and shear of the tissue culture.
    Type: Grant
    Filed: September 22, 2020
    Date of Patent: November 8, 2022
    Assignee: Steakholder Foods, LTD.
    Inventor: Sharon Fima
  • Patent number: 11490603
    Abstract: The present invention relates to a brain tumor animal model that directly reflects the phenomenon in a human patient and a method of preparing the same, and more specifically, a brain tumor animal model that mutations are introduced into p53, Pten, and EGFR genes, a screening method of a therapeutic agent for a brain tumor using the animal model, and a preparing method thereof.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: November 8, 2022
    Assignees: KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY, YONSEI UNIVERSITY, UNIVERSITY—INDUSTRY FOUNDATION (UIF)
    Inventors: Seok Gu Kang, Jeong Ho Lee, Joo Ho Lee, Jeong Eun Lee
  • Patent number: 11464640
    Abstract: An anatomically-shaped, human bone graft may be cultivated ex vivo using a bioreactor capable of perfusing large complex porous scaffolds. Scaffolds derived from image-based modeling of a target are seeded with human mesenchymal stem cells and cultivated. A bioreactor configured to house complex three-dimensional scaffold geometries provides controlled flow for perfusion of the cells. Dense uniform cellular growth can be attained throughout the entire scaffold as a result of the medium perfusion. In an embodiment, the bioreactor has a mold into which perfusion medium is pumped under pressure and multiple ports through which the medium exits the mold.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: October 11, 2022
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Gordana Vunjak-Novakovic, Warren Grayson, Keith Yeager
  • Patent number: 11466290
    Abstract: Described herein are donor vectors and systems for use in in vivo dual recombinase-mediated cassette exchange. Also described are animal models for consistent, rigorous, and facile investigation of transgene expression. Further described are methods of screening for therapeutic drugs using these animal models, and methods of treatment.
    Type: Grant
    Filed: December 30, 2016
    Date of Patent: October 11, 2022
    Assignee: Cedars-Sinai Medical Center
    Inventors: Joshua Breunig, Moise Danielpour, Gi Bum Kim
  • Patent number: 11459560
    Abstract: The present disclosure relates to methods and compositions for reprogramming cells to a pluripotent state. In particular, it relates to an integration- and feeder cell-free method for reprogramming primary human fibroblast cells to induced pluripotent stem cells (iPSCs).
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: October 4, 2022
    Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO
    Inventors: Igor Kogut, Dennis R. Roop, Ganna Bilousova
  • Patent number: 11447752
    Abstract: Disclosed is a method for producing an in vitro model for blood-brain barrier, including (a) a culturing conditionally immortalized astrocytes on one surface of a porous membrane and culturing conditionally immortalized brain pericytes on the other surface of the porous membrane, until both of the cells become a sheet; (b) culturing conditionally immortalized brain microvascular endothelial cells in a culture vessel, until the cells become a sheet; (c) peeling off the sheet of conditionally immortalized brain microvascular endothelial cells; (d) allowing the sheet of conditionally immortalized brain microvascular endothelial cells to come into contact with the sheet of conditionally immortalized brain pericytes, so that the sheets are arranged in layers; and (e) co-culturing a cell culture comprising three layers consisting of the sheet of conditionally immortalized brain microvascular endothelial cells, the sheet of conditionally immortalized brain pericytes, and the sheet of conditionally immortalized astro
    Type: Grant
    Filed: March 22, 2017
    Date of Patent: September 20, 2022
    Assignee: YAMAGUCHI UNIVERSITY
    Inventors: Yukio Takeshita, Takashi Kanda
  • Patent number: 11446332
    Abstract: Provided herein are methods and compositions for dynamically controlling and targeting multiple immunosuppressive mechanisms in cancer. Some aspects provide cells engineered to produce multiple effector molecules, each of which modulates a different immunosuppressive mechanisms of a tumor, as well as methods of using the cells to treat cancer, such as ovarian, breast, or colon cancer.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: September 20, 2022
    Assignee: SENTI BIOSCIENCES, INC.
    Inventors: Timothy Kuan-Ta Lu, Russell Morrison Gordley, Jack Tzu-Chiao Lin, Brian Scott Garrison, Philip Janmin Lee, Alba Gonzalez-Junca, Don-Hong Wang
  • Patent number: 11439666
    Abstract: Disclosed herein are methods and compositions for inactivating TCR genes, using zinc finger nucleases (ZFNs) comprising a zinc finger protein and a cleavage domain or cleavage half-domain in conditions able to preserve cell viability. Polynucleotides encoding ZFNs, vectors comprising polynucleotides encoding ZFNs and cells comprising polynucleotides encoding ZFNs and/or cells comprising ZFNs are also provided. Disclosed herein are also methods and compositions for expressing a functional exogenous TCR in the absence of endogenous TCR expression in T lymphocytes, including lymphocytes with a central memory phenotype. Polynucleotides encoding exogenous TCR, vectors comprising polynucleotides encoding exogenous TCR and cells comprising polynucleotides encoding exogenous TCR and/or cells comprising exogenous TCR are also provided.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: September 13, 2022
    Assignees: Sangamo Therapeutics, Inc., Ospedale San Raffaele srl
    Inventors: Maria Chiara Bonini, Pietro Genovese, Philip D. Gregory, Michael C. Holmes, Luigi Naldini, David Paschon, Elena Provasi, Lei Zhang
  • Patent number: 11419898
    Abstract: Provided herein are methods and compositions for dynamically controlling and targeting multiple immunosuppressive mechanisms in cancer. Some aspects provide cells engineered to produce multiple effector molecules, each of which modulates a different immunosuppressive mechanisms of a tumor, as well as methods of using the cells to treat cancer, such as ovarian, breast, or colon cancer.
    Type: Grant
    Filed: March 31, 2021
    Date of Patent: August 23, 2022
    Assignee: SENTI BIOSCIENCES, INC.
    Inventors: Timothy Kuan-Ta Lu, Russell Morrison Gordley, Jack Tzu-Chiao Lin, Brian Scott Garrison, Philip Janmin Lee, Alba Gonzalez-Junca, Don-Hong Wang, Daniel Frimannsson
  • Patent number: 11406739
    Abstract: Provided is a method for construction of bone substitutes efficient in the repair of large bone defects. The method for constructing such medical products includes three-dimensional printing of a bioresorbable scaffold and its activation by gene constructions. Produced medicinal products may serve as an efficient alternative to bone autografts.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: August 9, 2022
    Assignee: “NEXTGEN” COMPANY LIMITED
    Inventors: Roman Vadimovich Deev, Artur Aleksandrovich Isaev, Ilya Yadigerovich Bozo, Vladimir Sergeevich Komlev, Alexey Yurevich Drobyshev
  • Patent number: 11390835
    Abstract: A three-dimensional cell growth medium is described. The cell growth medium may comprise hydrogel particles swollen with a liquid cell growth medium to form a granular gel yield stress material which undergoes a phase transformation from a solid phase to a liquid-like phase when an applied stress exceeds the yield stress. Cells may be placed in the three-dimensional cell growth medium according to any shape or geometry, and may remain in place within the three-dimensional cell growth medium.
    Type: Grant
    Filed: May 7, 2016
    Date of Patent: July 19, 2022
    Assignee: University of Florida Research Foundation, Inc.
    Inventors: Wallace Gregory Sawyer, Thomas Ettor Angelini, Steven Craig Ghivizzani, Tapomoy Bhattacharjee, Glyn Daniel Palmer
  • Patent number: 11370845
    Abstract: The purpose of the present invention is to produce a chimeric antigen receptor (CAR) specific to glypican-1 (GPC-1) and to treat squamous cell carcinoma with genetically modified cells capable of expressing the CAR. The present invention provides: a chimeric antigen receptor for use in the treatment and/or prevention of squamous cell carcinoma, said chimeric antigen receptor comprising an extracellular domain capable of binding to GPC-1, a transmembrane domain and one or multiple intracellular domains, wherein at least one of the intracellular domains is an intracellular domain containing a primary cytosolic signaling sequence or an intracellular domain containing both a primary cytosolic signaling sequence and a secondary cytosolic signaling sequence; a genetically modified cell capable of expressing the chimeric antigen receptor; and a cell preparation containing the cell.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: June 28, 2022
    Assignees: Keio University, NATIONAL UNIVERSITY CORPORATION KOCHI UNIVERSITY
    Inventors: Tomonori Yaguchi, Kenji Morii, Yutaka Kawakami, Daiki Kato, Tetsuji Naka, Satoshi Serada, Minoru Fujimoto
  • Patent number: 11371022
    Abstract: The invention relates to a method of creating a human blood-brain barrier (BBB) model from the differentiation of human pluripotent stem cells (hPSCs), wherein the BBB exhibits sustained transendothelial electrical resistances (TEER) over 2000 ?·cm2 for at least 3 days after seeding.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: June 28, 2022
    Assignee: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Tae-Eun Park, Anna Herland, Edward Anthony Fitzgerald, Donald Elliot Ingber
  • Patent number: 11357244
    Abstract: The substrates, systems, and methods described herein relate to textured substrates for preparing a comestible meat product. Substrates and methods are described herein for controlling one or more of growth, adhesion, retention, and/or release of cells (e.g., of a cell sheet) on or from the surface of the substrate. A method of preparing a comestible meat product may include applying a plurality of non-human cells to at least one patterned texture substrate, growing the cells on the patterned texture substrate to form the comestible meat product, and separating the comestible meat product from the patterned texture substrate. The patterned texture allows for improved growth, adhesion, retention, and/or release of cells as compared to another surface not comprising the patterned texture. In some embodiments, the cell culture substrate surfaces include a plurality of regions corresponding to a plurality of patterned textures.
    Type: Grant
    Filed: December 22, 2020
    Date of Patent: June 14, 2022
    Assignee: Upside Foods, Inc.
    Inventors: Matthew Leung, Asha Godbole, George C. Engelmayr, Jr., Nicholas J. Genovese, Uma S. Valeti, Kathleen Carswell
  • Patent number: 11344583
    Abstract: Compositions are provided that contain biologically active components of amniotic fluid including growth factors and other proteins, carbohydrates, lipids, and metabolites. The compositions containing biologically active components of amniotic fluid can be useful for a range of therapeutic treatments including joint and soft tissue repair, regulation of skin condition, and for use in organ preservation, such as for use in organ transplant procedures. Advantages of the compositions include that they can be reproducibly produced, without the inherent variability of amniotic fluid from individual donors, and that they are free of fetal waste.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: May 31, 2022
    Assignee: Merakris Therapeutics Inc.
    Inventors: William Samuel Fagg, IV, Thomas Christopher Broderick
  • Patent number: 11345890
    Abstract: The present invention features a neural organoid that recapitulates in vitro most characteristics of the brain (e.g., human), and methods of using this neural organoid to study disease and to identify therapeutic agents for the treatment of neurological diseases and disorders.
    Type: Grant
    Filed: January 12, 2017
    Date of Patent: May 31, 2022
    Inventor: Rene Anand
  • Patent number: 11339196
    Abstract: The present invention relates to a cell therapeutic agent comprising a stem cell expressing Lin28, a pharmaceutical composition comprising a stem cell expressing Lin28 for the prevention or treatment of a neurological disorder, a bone disorder, a muscular system disorder, an epithelium-related disorder or a blood-related disorder, and a method for treating a neurological disorder, a bone disorder, a muscular system disorder, an epithelium-related disorder or a blood-related disorder using the composition. A stem cell excellent in terms of differentiation potency to various tissue cells and renewal ability can be prepared by introducing Lin28, which regulates an embryonic development procedure, or a vector expressing Lin28 during stem cell culturing, and by culturing the cell.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: May 24, 2022
    Assignee: Industry-University Cooperation Foundation Hanyang University
    Inventors: Sang-Hun Lee, Yong Hee Rhee, Chang-Hwan Park, Mi-Yoon Chang, Yanuar Alan Sulistio, Ji Yun Ko
  • Patent number: 11339399
    Abstract: The present invention provides cell lines for high efficiency genome editing using cas/CRISPR systems, methods of generating such cells lines, and methods of generating mutations in the genome of an organism using such cell lines.
    Type: Grant
    Filed: December 31, 2015
    Date of Patent: May 24, 2022
    Assignee: Viridos, Inc.
    Inventors: John Verruto, Eric Moellering